April 23, 2026 4:34pm

There is also no ignoring earnings reporting season

“Tech stocks are the primary driver of the rebound since the conflict, accounting for roughly 57% of the rally even though it represents just a 35% weight in the index.” <UBS>

Econs, now plus oil seem to always “whack” and destabilize the Cell & Gene Therapy sector’s pricing

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

RMi Pre-opening: None, why keep repeating the warnings from Wednesday’s closing bell

Wednesday’s RMi Closing Bell: Da … https://www.regmedinvestors.com/articles/14392

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Thursday: The Dow closed DOWN -179.71 points or -0.36%, the S&P closed DOWN -29.50 points or -0.41% while the Nasdaq closed DOWN -219.063 points or -0.89%

  • Theme of the session: pullback

Thursday (my) 40-company covered sector’s advance/decline line opened negative with 11 incliners, 26 decliners and 3 flats, ending with a negative close of 7 incliner, 30 decliners and 3 flat

  • It’s time for fundamentals and trial “stones” to be MORE considered VALUED

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Initial jobless claims were slightly higher than expected last week but still in keeping with a subdued level of layoffs. First-time filings totaled a seasonally adjusted 214,000 for the week ending April 18, up 6,000 from the prior period and above the consensus estimate for 210,000. Continuing claims, which run a week behind, edged up to 1.82 M.
  • PMI readings better than estimates for April. Business activity in the U.S. has been stronger than expected so far in April, according to separate S&P Global measures. The manufacturing and services gauges both turned in upside surprises for the month: 54.0 against a 52.5 forecast in manufacturing, and 51.3 vs. a 51.0 estimate on the services side. The manufacturing reading marked the best showing since May 2022 as production and new orders both hit multi-year highs. Still, expectations for the conditions ahead were muted.

The CBOE Fear (VIX) index, Thursday closed at 19.29, after Wednesday’s 18.74, Tuesday’s 20.59, Monday’s 19.04, Friday’s 17.39 and last Thursday’s 17.81

Metrics: Wednesday …

  • The RUT was down -15.68 points or -0.56%,
  • The XLV was sown -0.16 points or -0.11%,
  • The NBI was down -87.05 points or -1.44%;
  • The XBI was down -2.83 points or -2.06%
  • The IWM was down -0.98 or -0.35%;
  • The IBB was down -2.83 points or -1.62%,
  • The VIX was up +0.37 points or +1.96% at to 19.29
  • The SPX was down -34.54 or -0.48% to 7,103.36

 

Q2/26 – 1 holiday, 1 neutral, 6 negative and 8 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Thursday Closing UP (7 of 7) 

  • Alnylam Pharmaceuticals (ALNY +$3.21 after Wednesday’s +$2.15 after Tuesday’s -$2.51 after Monday’s +$1.28),
  • Arrowhead Pharmaceuticals (ARWR +$0.48 after Wednesday’s +$2.87 after Tuesday’s +$1.80),
  • AxoGen (AXGN +$0.41 after Wednesday’s +$1.11 after Tuesday’s -$1.34 after Monday’s -$1.27),
  • Supernus Therapeutics (SUPN +$0.10 after Wednesday’s +$1.17 after Tuesday’s -$2.13),
  • MiMedx (MDXG +$0.04)
  • Vericel (VCEL +$0.03 after Wednesday’s +$0.70 after Tuesday’s -$2.14 after Monday’s +$0.13),

Flat (3)

  • Brainstorm Cell Therapeutics (BCLI),
  • Generation Bio (GBIO) – acquired
  • Precigen (PGEN)

Thursday’s Closing DOWN (10 of 30): 

  • IQVA Holdings (IQV -$14.52 after Wednesday’s -$0.47 after Tuesday’s -$1.18 after Monday’s +$0.41),
  • BioNTech (BNTX -$3.04 after Wednesday’s -$3.00 after Tuesday’s +$6.41 after Monday’s +$2.27),
  • Moderna (MRNA -$2.75 after Wednesday’s +$1.37),
  • Vertex (VRTX -$2.57 after Wednesday’s +$1.08 after Tuesday’s -$2.59 after Monday’s -$2.02),
  • Beam Therapeutics (BEAM -$1.53 after Wednesday’s +$1.00),
  • CRISPR Therapeutics (CRSP -$1.24 after Wednesday’s +$0.88 after Tuesday’s -$2.15 after Monday’s -$0.30),
  • Capricor Therapeutics (CAPR -$1.14 after Wednesday’s -$0.34 after Tuesday’s +$1.13 after Monday’s -$0.49),
  • BioLife Solutions (BLFS -$1.08),
  • Lenz Therapeutics (LENZ -$0.86),
  • Dyne Therapeutics (DYN -$0.77),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

The Nasdaq slipped from record highs on Thursday after the 1st big wave of tech earnings failed to save the day.

  • WTI crude oil futures rose 3.1% to $95.85 a barrel. Brent crude rose 3.1% to $105.07.

What else can one say or write, it’s been written for days this week - war, oil and uncertainty as optimism lacks!

 

April 4th Week:

  • 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

April 3rd Week:

  • 4/17 - Friday closed positive with 33 incliners, 5 decliners and 2 flats
  • 4/16 - Thursday closed negative with 12 incliners, 26 decliners and 2 flats
  • 4/15 – Wednesday closed positive with 26 incliners, 12 decliners and 2 flats
  • 4/14 - Tuesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 4/13 - Monday closed positive with 33 incliners, 5 decliners and 2 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28
  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • IQVIA Holdings (IQV) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
  • Vericel (VCEL) – Thursday, 5/7

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and Supernus Therapeutics (SUPN)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Moderna (MRNA)
  • Tuesday: BioNTech (BNTX), Arrowhead Pharmaceuticals (ARWR) and Capricor Therapeutics (CAPR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and BioLife Solutions BLFS)

The worst three (3) in the session: Losers’

  • Thursday: IQVA Holdings (IQV), BioNTech (BNTX) and Vertex (VRTX)
  • Wednesday:  BioNTech (BNTX), IQVA Holdings (IQV) and Mesoblast (MESO)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Monday: Vertex (VRTX), AxoGen (AXGN) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.